Cover Image

Editorial: Steroid‐Induced Diabetes in Autoimmune Hepatitis—A Call for Treatment Optimisation. Authors' Reply

Fuente: Wiley Open Access

Saved in:

Bibliographic Details
Main Author:	Sarah Flatley
Format:	Artículo Open Access
Published:	Wiley 2026
Subjects:	Alimentary Pharmacology & Therapeutics
Online Access:	Acceder al recurso
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Editorial: Steroid‐Induced Diabetes in Autoimmune Hepatitis—A Call for Treatment Optimization
by: Pranab M. Barman
Published: (2026)

Letter: Drug‐Induced Autoimmune‐Like Hepatitis—A Trigger on the Disease Spectrum. Authors' Reply
by: Pinelopi Arvaniti, et al.
Published: (2025)

Letter on ‘Clinical Features of Portal Hypertension and Their Prognostic Implications in Patients With Autoimmune Hepatitis’: Authors' Reply
by: Lukas Burghart, et al.
Published: (2026)

Editorial: Risk of Incident Type 2 Diabetes and Prediabetes in Patients With Direct Acting Antiviral‐Induced Cure of Hepatitis C Virus Infection—Authors' Reply
by: Yu‐Ping Chang, et al.
Published: (2025)

Unveiling Drug‐Induced Autoimmune‐Like Hepatitis in Autoimmune Hepatitis Patients: A Multicenter Retrospective Study
by: Pinelopi Arvaniti, et al.
Published: (2025)

Letter: A Patient Centric Approach to Tapering Steroids in Steroid Responsive Moderate to Severely Active Ulcerative Colitis. Authors' Reply
by: Amol N. Patil, et al.
Published: (2026)

Letter on ‘Unveiling Drug‐Induced Autoimmune‐Like Hepatitis in Autoimmune Hepatitis Patients: A Multicenter Retrospective Study’
by: Muhammad Ibrahim Khalil, et al.
Published: (2025)

Editorial: Advancing HCC Surveillance in Hepatitis B With Biomarker‐Based Strategy—Authors' Reply
by: Tanat Saeoui, et al.
Published: (2025)

Letter: Optimising Hepatitis B Vaccination in Inflammatory Bowel Disease – Expanding Strategies Beyond Double‐Dose Recombinant Vaccination. Authors' Reply
by: Anupam Kumar Singh, et al.
Published: (2026)

Editorial: Diabetes Management in Cirrhosis—The Window of Opportunity Before Decompensation. Authors' Reply
by: Mary Yue Wang, et al.
Published: (2026)

Editorial: Ultralow HBsAg Levels and the Prediction of Cure in Chronic Hepatitis B—Authors' Reply
by: Jian Wang, et al.
Published: (2025)

Editorial: Cephalosporin‐Induced Liver Injury—Interesting but Tricky. Authors' Reply
by: Raj Vuppalanchi, et al.
Published: (2025)

Editorial: The Relevance of Hepatic Flares and Quantitative Hepatitis B Surface Antigen After Stopping HBV Polymerase Inhibitors—Authors' Reply
by: Ying‐Nan Tsai, et al.
Published: (2025)

Letter: Predictors of Corticosteroid Response in Alcohol‐Related Hepatitis—Authors' Reply
by: Francisco Idalsoaga, et al.
Published: (2025)

Editorial: When Yeast Turns Beast—Unmasking an Overlooked Threat in Alcohol‐Related Hepatitis. Authors' Reply
by: Vincent Mallet, et al.
Published: (2025)

Editorial: H. pylori Treatment—Old Ingredients in New Effective Regimens. Authors' Reply
by: Olga P. Nyssen, et al.
Published: (2025)

Editorial: Using HBcrAg and HBsAg Kinetics to Optimise Monitoring After Nucleo(s)tide Analogue Withdrawal. Authors' Reply
by: Yasuhito Tanaka, et al.
Published: (2026)

Editorial: Beyond Viral Eradication—Cardiometabolic Risk and Cardiovascular Outcomes After SVR in Chronic Hepatitis C. Authors' Reply
by: Pei‐Chien Tsai, et al.
Published: (2026)

Editorial: Addressing Unmet Needs and Socioeconomic Disparity in Patients With Autoimmune Hepatitis
by: Seren Gedallovich, et al.
Published: (2024)

Editorial: ‘Risk‐Adapted Starting Ages of Colorectal Cancer Screening for People With Diabetes or Metabolic Syndrome’. Authors' Reply
by: Hermann Brenner, et al.
Published: (2025)

Editorial: Residual HCC Risk After Hepatitis C Cure—Can Polygenic Risk Scores Refine Surveillance? Authors' Reply
by: Yu‐Sheng Lin, et al.
Published: (2026)

Letter: Addressing Gaps in Hospital‐Based Hepatitis C Screening—Insights and Recommendations. Authors' Reply'
by: Alberto Ferrarese, et al.
Published: (2025)

Editorial: Getting to the Heart of the Matter in IBD—Authors' Reply
by: Ramin Ebrahimi, et al.
Published: (2025)

Editorial: Clinical Impact of Lipid Profile Change After DAA Treatment in CHC Patients—Authors' Reply
by: Zahra Sarrafan‐Chaharsoughi, et al.
Published: (2025)

Editorial: Food for Thought—Addressing the Nuances of Diet and Mood When Evaluating Dietary Intervention in IBS. Authors' Reply
by: Anthony O'Connor, et al.
Published: (2024)

Letter: Enhancing Risk‐Adapted Colorectal Cancer Screening for People With Diabetes—Authors' Reply
by: Teresa Seum, et al.
Published: (2025)

Letter on ‘Meta‐Analysis: Mortality Trends and Risk Factors in Severe Alcohol‐Associated Hepatitis’—Authors' Reply
by: Francisco Idalsoaga, et al.
Published: (2025)

Editorial: Optimal Treatment for Older Patients With Inflammatory Bowel Disease: How to Detect and Manage Frailty? Authors' Reply
by: A. B. Fons, et al.
Published: (2026)

Editorial: Targeting Urgency in IBD —A Historical Divide. Authors' Reply
by: Parul Tandon, et al.
Published: (2025)

Editorial: Predicting Hepatocellular Cancer in Clinical Practice. Authors' Reply
by: Shuaibing Ying, et al.
Published: (2026)

Editorial: Allostatic Load and Inflammatory Bowel Disease. Authors' Reply
by: Jianhui Zhao, et al.
Published: (2024)

Editorial: To Stop or Not to Stop, Is It Still a Question? Authors' Reply
by: Jeongkuk Seo, et al.
Published: (2024)

Editorial: Association of Antibiotic Exposure With Microscopic Colitis—Authors' Reply
by: Máté Szilcz, et al.
Published: (2025)

Editorial: Evaluating the Prevalence of Metabolic Dysfunction‐Associated Steatotic Liver Disease in Patients With Type 2 Diabetes and Hyperferritinaemia—Authors' Reply
by: Maral Amangurbanova, et al.
Published: (2024)

Letter: Lubiprostone Treatment for MASLD—Gender Imbalance and Blinding Considerations. Authors' Reply
by: Mohamed El‐Kassas, et al.
Published: (2025)

Editorial: Predicting Hepatocellular Carcinoma Development in Chronic Hepatitis B Patients With Metabolic Dysfunction—Do Existing Scores Clear the Bar? Authors' Reply
by: Lesley A. Patmore, et al.
Published: (2025)

Letter: “Tenofovir Alafenamide—The ‘Star of Potential’ for Long‐Term Chronic Hepatitis B Treatment. A Deep‐Dive Analysis of Phase 3 Clinical Trials.” Authors' Reply
by: Maria Buti
Published: (2025)

Letter: Reassessing Tenofovir Alafenamide Use Throughout Pregnancy—A New Horizon in Hepatitis B Therapy. Authors' Reply
by: Xingfei Pan, et al.
Published: (2025)

Letter: Advancing Serologic Classification in Indeterminate Chronic Hepatitis B Through Dynamic and Integrated Frameworks—Authors' Reply
by: Rui Huang, et al.
Published: (2025)

Letter: Refining Mortality Estimates in Severe Alcohol–Associated Hepatitis—Addressing Heterogeneity and Prognostic Assessment. Authors' Reply
by: Francisco Idalsoaga, et al.
Published: (2025)